Products for Research Use Only

Dolastatin 15

CAT: 0804-HY-P1126Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P1126Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin[1][2][3].
CAS Number
123884-00-4
Product Name Alternative
DLS 15
UNSPSC
12352209
Target
ADC Payload; Apoptosis; Microtubule/Tubulin
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dolastatin-15.html
Solubility
10 mM in DMSO
Smiles
O=C(N(C1=O)[C@H](C(OC)=C1)CC2=CC=CC=C2)[C@H](C(C)C)OC([C@H](CCC3)N3C([C@H](CCC4)N4C([C@H](C(C)C)N(C)C([C@H](C(C)C)NC([C@@H](N(C)C)C(C)C)=O)=O)=O)=O)=O
Molecular Formula
C45H68N6O9
Molecular Weight
837.06
References & Citations
[1]Bai R, et al. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992 Jun 23;43 (12) :2637-45.|[2]Sato M, et al. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int J Oncol. 2007 Jun;30 (6) :1453-9.|[3]Gianolio DA, et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol. 2012 Sep;70 (3) :439-49.|[4]Ali MA, et al. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. Anticancer Res. 1998 Mar-Apr;18 (2A) :1021-6.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
Auristatin